CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)
CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®) INGELHEIM, Germany–(BUSINESS WIRE)– Today, the Committee for Medicinal Products for Human...